Can you take Delgocitinib topical with Ibrance?
1 drug interaction and 8 additional warnings found for the following 2 drugs:
- delgocitinib topical
- Ibrance (palbociclib)
Drug interactions
Moderate drug interactions
Moderate:
palbociclib delgocitinib topical
Applies to: Ibrance (palbociclib) and delgocitinib topical
Using palbociclib together with delgocitinib topical can increase the risk of serious and potentially life-threatening infections, as well as some cancers.
Talk to your doctor if you have any questions or concerns.
Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications.
Contact your doctor immediately if you develop signs and symptoms of infection such as:
- fever
- chills
- diarrhea
- sore throat
- muscle aches
- shortness of breath
- blood in phlegm
- weight loss
- red or inflamed skin
- body sores
- pain or burning during urination
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Moderate food/lifestyle interactions
Moderate:
palbociclib Food/Lifestyle
Applies to: Ibrance (palbociclib)
Palbociclib oral capsules (Ibrance) should be taken with food to help with its absorption. Palbociclib oral tablets (Ibrance) may be taken with or without food.
Do not consume grapefruit or grapefruit juice during treatment with palbociclib. Grapefruit and grapefruit juice can interact with palbociclib and increase the levels of palbociclib in your body.
You may be more likely to experience side effects such as:
- nausea
- vomiting
- diarrhea
- loss of appetite
- mouth sores
- hair loss
- weakness
- pain, numbness, or tingling in the hands and feet
- impaired bone marrow function resulting in low numbers of different types of blood cells, which can increase the risk of anemia, bleeding problems, and infections
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Disease interactions
7 potential interactions Applies to: 7 conditions, including Fever, Liver Disease, Interstitial Lung Disease, Neutropenia, and Renal Dysfunction.
Fever
Moderate:
Ibrance
The palbociclib in Ibrance has a moderate potential interaction with Fever.
The use of palbociclib may cause neutropenia, including febrile neutropenia and neutropenic sepsis. It is recommended to monitor complete blood counts prior to starting treatment and at the beginning of each therapy cycle with palbociclib, as well as on Day 15 of the first 2 cycles, and as clinically indicated thereafter. Dose interruption, dose reduction, or delay in starting treatment cycles is recommended for patients who develop Grade 3 or 4 neutropenia. Care and close monitoring is recommended, in particular for any episodes of fever.
Interstitial Lung Disease
Moderate:
Ibrance
The palbociclib in Ibrance has a moderate potential interaction with Interstitial Lung Disease.
The use of certain multikinase inhibitors has been associated with pulmonary toxicity. Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported. Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation. If ILD is confirmed, these agents should be permanently discontinued and appropriate measures should be instituted. Treatment should be immediately withheld in patients diagnosed with ILD/pneumonitis and permanently discontinued if no other potential causes of ILD/pneumonitis have been identified.
Liver Disease
Moderate:
Ibrance
The palbociclib in Ibrance has a moderate potential interaction with Liver Disease.
Based on a population pharmacokinetic analysis with palbociclib mild hepatic impairment had no effect on the exposure of palbociclib. Close monitoring is recommended when using this agent in patients with moderate or severe hepatic impairment as the pharmacokinetics of palbociclib have not been studied in these patients. Dose modification of concomitant medications may be needed based of hepatic impairment.
Neutropenia
Moderate:
Ibrance
The palbociclib in Ibrance has a moderate potential interaction with Neutropenia.
The use of palbociclib may cause neutropenia, including febrile neutropenia and neutropenic sepsis. It is recommended to monitor complete blood counts prior to starting treatment and at the beginning of each therapy cycle with palbociclib, as well as on Day 15 of the first 2 cycles, and as clinically indicated thereafter. Dose interruption, dose reduction, or delay in starting treatment cycles is recommended for patients who develop Grade 3 or 4 neutropenia. Care and close monitoring is recommended, in particular for any episodes of fever.
Premenopausal Anovulation
Moderate:
Ibrance
The palbociclib in Ibrance has a moderate potential interaction with Premenopausal Anovulation.
Pre/perimenopausal women treated with the combination palbociclib plus fulvestrant therapy should be treated with luteinizing hormone-releasing hormone (LHRH) agonists according to current clinical practice standards. Care and close monitoring is recommended.
Pulmonary Impairment
Moderate:
Ibrance
The palbociclib in Ibrance has a moderate potential interaction with Pulmonary Impairment.
The use of certain multikinase inhibitors has been associated with pulmonary toxicity. Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported. Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation. If ILD is confirmed, these agents should be permanently discontinued and appropriate measures should be instituted. Treatment should be immediately withheld in patients diagnosed with ILD/pneumonitis and permanently discontinued if no other potential causes of ILD/pneumonitis have been identified.
Renal Dysfunction
Moderate:
Ibrance
The palbociclib in Ibrance has a moderate potential interaction with Renal Dysfunction.
Based on a population pharmacokinetic analysis with palbociclib mild and moderate renal impairment had no effect on the exposure of palbociclib. Close monitoring is recommended when using this agent in patients with severe renal impairment as the pharmacokinetics of palbociclib in these patients have not been studied.
Report options
More resources
delgocitinib topical
A total of 334 drugs are known to interact with delgocitinib topical.
- Delgocitinib topical is in the drug class miscellaneous topical agents.
- Delgocitinib topical is used to treat Eczema.
Ibrance
A total of 513 drugs are known to interact with Ibrance.
- Ibrance is in the drug class CDK 4/6 inhibitors.
- Ibrance is used to treat the following conditions:
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.